| __timestamp | Intra-Cellular Therapies, Inc. | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 1802274 |
| Thursday, January 1, 2015 | 18187286 | 2512761 |
| Friday, January 1, 2016 | 24758063 | 2894488 |
| Sunday, January 1, 2017 | 23666957 | 8096274 |
| Monday, January 1, 2018 | 30099855 | 7985229 |
| Tuesday, January 1, 2019 | 64947625 | 8994597 |
| Wednesday, January 1, 2020 | 186363444 | 29772000 |
| Friday, January 1, 2021 | 272611040 | 33907000 |
| Saturday, January 1, 2022 | 358782000 | 26579000 |
| Sunday, January 1, 2023 | 409864000 | 49868547 |
Cracking the code
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustainable growth. This analysis compares the SG&A expenses of Intra-Cellular Therapies, Inc. and Verona Pharma plc from 2014 to 2023. Over this period, Intra-Cellular Therapies, Inc. saw a staggering increase of nearly 3,900% in their SG&A expenses, peaking at approximately $410 million in 2023. In contrast, Verona Pharma plc experienced a more modest rise of around 2,700%, reaching nearly $50 million in the same year. This stark difference highlights the varying strategies and scales of operation between the two companies. While Intra-Cellular Therapies, Inc. has aggressively expanded its administrative and sales efforts, Verona Pharma plc has maintained a more conservative approach. Understanding these trends provides valuable insights into the financial strategies of these biopharma players.
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Intra-Cellular Therapies, Inc.
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Verona Pharma plc
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Catalent, Inc. and Verona Pharma plc
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.